Monte Rosa Therapeutics, a biotechnology company originally formed as a spinout from science at The Institute of Cancer Research, London, partly funded by Cancer Research UK, is now listed on the Nasdaq stock exchange in New York.

Monte Rosa Therapeutics, a company originally formed as a spinout from Cancer Research UK-funded drug discovery research at the ICR, in collaboration with Versant’s drug discovery engine Ridgeline Therapeutics, has closed a $96m ‘series B’ financing from investors to support the further development of its drug pipeline.

A company formed as a spinout from Cancer Research UK-funded science at The Institute of Cancer Research, London, has been publicly launched – revealing $32.5m in funding and a library of innovative anti-cancer compounds.